These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31723782)

  • 1. Ruxolitinib for the Treatment of Essential Thrombocythemia.
    Gunawan A; Harrington P; Garcia-Curto N; McLornan D; Radia D; Harrison C
    Hemasphere; 2018 Aug; 2(4):e56. PubMed ID: 31723782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
    Bose P; Masarova L; Verstovsek S
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
    Mesa RA; Scherber RM; Geyer HL
    Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
    Harrison CN; Mead AJ; Panchal A; Fox S; Yap C; Gbandi E; Houlton A; Alimam S; Ewing J; Wood M; Chen F; Coppell J; Panoskaltsis N; Knapper S; Ali S; Hamblin A; Scherber R; Dueck AC; Cross NCP; Mesa R; McMullin MF
    Blood; 2017 Oct; 130(17):1889-1897. PubMed ID: 29074595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
    Radia D; Geyer HL
    Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and management of myelofibrosis in the era of JAK inhibitors.
    Keohane C; Radia DH; Harrison CN
    Biologics; 2013; 7():189-98. PubMed ID: 23990704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
    Palmer J; Mesa R
    Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
    Vaddi K; Verstovsek S; Kiladjian JJ
    Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with ruxolitinib in the treatment of polycythaemia vera.
    Alimam S; Harrison C
    Ther Adv Hematol; 2017 Apr; 8(4):139-151. PubMed ID: 28491265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):277-86. PubMed ID: 25696867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
    Verstovsek S; Gotlib J; Gupta V; Atallah E; Mascarenhas J; Quintas-Cardama A; Sun W; Sarlis NJ; Sandor V; Levy RS; Kantarjian HM; Mesa RA
    Onco Targets Ther; 2013; 7():13-21. PubMed ID: 24368888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
    Mesa RA; Passamonti F
    Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
    Harrison CN; Nangalia J; Boucher R; Jackson A; Yap C; O'Sullivan J; Fox S; Ailts I; Dueck AC; Geyer HL; Mesa RA; Dunn WG; Nadezhdin E; Curto-Garcia N; Green A; Wilkins B; Coppell J; Laurie J; Garg M; Ewing J; Knapper S; Crowe J; Chen F; Koutsavlis I; Godfrey A; Arami S; Drummond M; Byrne J; Clark F; Mead-Harvey C; Baxter EJ; McMullin MF; Mead AJ
    J Clin Oncol; 2023 Jul; 41(19):3534-3544. PubMed ID: 37126762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase inhibitors: jackpot or potluck?
    Pavithran K; Pande SB
    Oncol Rev; 2012 Mar; 6(1):e13. PubMed ID: 25992203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress of JAK inhibitors for hematological disorders.
    Kirito K
    Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.
    Lee SS; Verstovsek S; Pemmaraju N
    J Immunother Precis Oncol; 2021 Aug; 4(3):117-128. PubMed ID: 35663101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
    Masarova L; Bose P; Verstovsek S
    Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.